Afferent Pharmaceuticals Inc.'s $55 million in series C money gives the firm enough to pay for work that includes the potential phase III trial with AF-219 in idiopathic pulmonary fibrosis (IPF) cough, enabling the firm to "drive this one home ourselves," CEO Kathleen Glaub told BioWorld Today. Read More
Agriculture considerations dominated the July 8 House Appropriations Committee hearing marking up budgets for the FDA and U.S. Department of Agriculture, but those in the life science industries may not have been cheered by the numbers posted by the committee prior to the hearing. Read More
Jun Bao, senior vice president and chief business officer of Shenogen Pharma Group, begins nearly every presentation about the company with a slide that features strikingly different images. Read More
Executives of a small biotech must feel some trepidation when forced to watch from the sidelines while their firm's pharma partner – the party often bringing the bulk of the financial backing, as well as the development and commercialization muscle, to the table – becomes itself the subject of an acquisition, a move that could result in reprioritization and termination of a once potentially lucrative collaboration. Read More
DUBLIN – Pierre Meulien will wrap up his five-year stint at the helm of Genome Canada at the end of next week, two months before he takes up the post of executive director of the Innovative Medicines Initiative (IMI), the €3.3 billion ($3.7 billion) public-private research partnership between the European Commission and the pharmaceutical industry. Read More
It proved a quick nod for Novartis AG's Entresto (sacubitril/valsartan), a combination ACE/neprilysin inhibitor that demonstrated an ability to reduce the rate of cardiovascular death and hospitalization related to heart failure in pivotal trials. Read More
Clovis Oncology Inc., of Boulder, Colo., said it started an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately $275 million. J.P. Morgan Securities LLC is acting as lead book-running manager and representative of the underwriters for the offering. Read More
Pieris Pharmaceuticals Inc., of Freising, Germany, said it is set to receive its third milestone payment for the second program in its discovery and development collaboration with Daiichi Sankyo Co. Ltd., of Tokyo, and seventh milestone payment overall under their multi-program agreement, inked in 2011. Read More
DBV Technologies SA, of Bagneux, France, said the FDA accepted an investigator-sponsored investigational new drug (IND) application for a phase IIa trial for the treatment of milk-induced eosinophilic esophagitis (EoE) in children using the company's patch therapy Viaskin Milk. Read More
Sponsors wanting to take advantage of Australia's new annual charge exemption (ACE) scheme have until July 22 to declare that their products had no financial turnover in the past fiscal year. Read More
